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Proteogenomics and Hi-C reveal transcriptional
dysregulation in high hyperdiploid childhood acute
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Hyperdiploidy, i.e. gain of whole chromosomes, is one of the most common genetic features
of childhood acute lymphoblastic leukemia (ALL), but its pathogenetic impact is poorly
understood. Here, we report a proteogenomic analysis on matched datasets from genomic
proﬁling, RNA-sequencing, and mass spectrometry-based analysis of >8,000 genes and
proteins as well as Hi-C of primary patient samples from hyperdiploid and ETV6/RUNX1-
positive pediatric ALL. We show that CTCF and cohesin, which are master regulators of
chromatin architecture, display low expression in hyperdiploid ALL. In line with this, a general
genome-wide dysregulation of gene expression in relation to topologically associating domain
(TAD) borders were seen in the hyperdiploid group. Furthermore, Hi-C of a limited number of
hyperdiploid childhood ALL cases revealed that 2/4 cases displayed a clear loss of TAD
boundary strength and 3/4 showed reduced insulation at TAD borders, with putative leu-
kemogenic effects.
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Aneuploidy, i.e., changes in chromosome numbers, is oneof the most common phenomena in cancer cells. In spiteof the huge efforts that have gone into understanding the
impact of somatic genetic events in cancer, the effects of aneu-
ploidy in tumorigenesis remain poorly understood. In fact, it is
even debated whether aneuploidy in itself may be a driver event
or if it is a passenger event without consequences in tumor
development1.
High hyperdiploid (51–67 chromosomes) pediatric B-cell
precursor acute lymphoblastic leukemia (BCP ALL) is one of
the most common malignancies in early childhood and is asso-
ciated with a median age at diagnosis of 3–5 years, a low white
blood cell count, and a favorable prognosis on contemporary
treatment protocols2. Genetically, its deﬁning feature is a non-
random aneuploidy consisting of extra chromosomes, most
commonly X, 4, 6, 10, 14, 17, 18, and 21. Approximately half of
cases also harbor mutations in the RTK–RAS pathway, primarily
KRAS, and 20% have mutations in histone modiﬁers such as
CREBBP, in addition to microdeletions of various genes involved
in B-cell differentiation/cell cycle control3,4. However, these
additional aberrations are seen only in a subset of the cases, are
sometimes gained or lost at relapse, and, when occurring, are
frequently subclonal, whereas the aneuploidy is uniformly
present3,4. Furthermore, we and others have shown that the
chromosomal gains in these cases are early and likely leukemia-
initiating aberrations, often arising several years before overt
disease3,5. Taken together, available data strongly indicate that the
aneuploidy is the main driver event in this type of leukemia, but
the underlying leukemogenic mechanism remains unclear.
Previous studies of the RNA expression pattern in high
hyperdiploid ALL have revealed a general upregulation of genes
on the gained chromosomes, hinting that dosage effects may
occur3,6,7. However, no detailed analysis of how this may
affect leukemogenesis has yet been published and it remains
unknown how the chromosomal gains may cause the develop-
ment of leukemia. Additionally, since genes are subject to post-
transcriptional control, the RNA expression level of a gene may
not be directly transferable to the protein level. To address this,
we performed a proteogenomic analysis of a series of pediatric
BCP-ALL, including high hyperdiploid and diploid/near-diploid
ETV6/RUNX1-positive cases, aiming to determine the effects of
aneuploidy. Besides demonstrating that the characteristic extra
chromosomes have an impact on the transcriptome and pro-
teome, we also present data suggesting that hyperdiploid leuke-
mia cases harbor aberrant chromatin organization that causes
genome-wide transcriptional dysregulation. Taken together, our
data give insight into the leukemogenesis of this common and
clinically important pediatric leukemia.
Results
Proteogenomic analysis of childhood BCP ALL. This study
comprised mass spectrometry (MS)-based analysis of the pro-
teome, whole genome and/or whole exome sequencing (WGS/
WES) for somatic mutations and structural events, SNP array
analysis for copy number assessment, and RNA-sequencing
(RNA-seq) for RNA expression in childhood BCP ALL. In total,
48 high hyperdiploid and 41 ETV6/RUNX1-positive cases were
investigated; the cohort analyzed with MS comprised eighteen
high hyperdiploid and nine ETV6/RUNX1-positive pediatric ALL
cases, as ascertained by chromosome banding, ﬂuorescence in situ
hybridization (FISH), SNP array analysis and reverse
transcriptase-PCR for the fusion transcript (Fig. 1a and Supple-
mentary Data 1 and 2).
MS data were generated via high-resolution isoelectric focusing
liquid chromatography mass spectrometry (HiRIEF LC-MS/MS)
workﬂow together with isobaric labeling (TMT10) for relative
quantiﬁcation between tumors8. In total, 10,981 proteins
originating from 10,138 genes were identiﬁed at 1% protein false
discovery rate (FDR) based on 174,966 unique peptides (Fig. 1b,
Supplementary Table 1 and Supplementary Data 3). For all
quantitative proteome analyses, we used a gene symbol centric
subset of 8480 genes that were quantiﬁed in each of the 27 tumors
(Fig. 1b).
Genomic and transcriptomic variation was observed at the
peptide level by searching HiRIEF LC-MS/MS spectra against a
customized sequence database, which included both human
RefSeq protein as well as somatic mutant and fusion sequences
derived from WGS/WES and RNA-seq. Although many SNPs
were seen in the protein dataset, none of the somatic mutations
could be detected. The ETV6/RUNX1 fusion could be identiﬁed at
the protein level in all nine cases from this subgroup.
Proteome analyses give improved biological insight in cancer.
For 8222 (97%) of the 8480 proteins detected by HiRIEF LC-MS/
MS, the expression of the corresponding mRNA could be ascer-
tained by rRNA-depleted RNA-seq (RiboZero RNA-seq) of the
same samples (Supplementary Data 4 and 5). Expression levels
were positively correlated for most (75%) mRNA–protein pairs
across the 27 samples, with 22% showing signiﬁcant correlation
(multiple-test adjusted P ≤ 0.05) and a mean Spearman’s corre-
lation coefﬁcient of 0.24 (Fig. 1c). This is similar to what has
previously been reported in colorectal cancer9, but lower than in
ovarian cancer and breast cancer10,11. When the correlation
scores were ascertained for different KEGG pathways, scores were
highest for specialized pathways, such as hematopoietic cell
lineage and amino acid metabolism, and lowest for house-keeping
functions, e.g., ribosomal and spliceosomal processes (Fig. 1d).
This is in line with the previous studies9–11 and demonstrates that
the level of expression of mRNA is not always directly translatable
to the protein level. To further test the post-translational gene
regulation effect on leukemia samples, we performed pairwise
correlation of gene/protein abundance for all 8222 proteins.
Similar to results previously obtained from the TCGA and
CPTAC datasets12, the correlation score for pairs of proteins
involved in the same protein complex displayed a degree of co-
regulation (mean Spearman’s correlation coefﬁcient= 0.19) that
was signiﬁcantly higher than that observed for random pairs
(mean Spearman’s correlation coefﬁcient= 0) (Supplementary
Fig. 1). A similar co-regulation effect could be seen at the tran-
script level (mean Spearman’s correlation coefﬁcient= 0.16), but
the correlation was signiﬁcantly lower than at the protein level
(two-tailed Mann–Whitney U-test P= 3.80e−20).
To explore the details of this relatively low correlation
between mRNA expression and protein abundance, we investi-
gated several aspects of mRNA and protein regulation. A global
comparison of stable and unstable mRNAs and their correspond-
ing proteins13 revealed signiﬁcantly higher correlation for genes
with similar stability on both the mRNA and protein levels
(Supplementary Fig. 2). Next, we investigated the potential
impact of miRNA-targeting. Genes regulated by miRNAs14
displayed signiﬁcantly lower mRNA and protein correlations,
showing a role for post-transcriptional RNA regulation (Supple-
mentary Fig. 2). We also observed that protein level regulation by
the ubiquitin–proteasome pathway15 affected the correlations
since genes with low mRNA–protein correlations were signiﬁ-
cantly more frequently targeted by the proteasome (Supplemen-
tary Fig. 2). Consistent with this result, an analysis of the protein
degradation rate also showed that genes with low mRNA–protein
correlations were enriched among rapidly degrading proteins16
(Supplementary Fig. 2). Interestingly, we observed that protein
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subcellular localization had an effect as cytosolic and proteins
residing in the plasma membrane, endoplasmic reticulum and the
Golgi (i.e., secretory proteins) exhibited increased mRNA-protein
correlations whilst nuclear and mitochondrial proteins did not
(Supplementary Fig 2). Finally, we also observed that mRNA and
proteins that were differentially expressed between hyperdiploid
and ETV6/RUNX1-positive leukemia had higher mRNA-protein
correlations (Supplementary Fig. 2). This ﬁts with the observation
in Orre et al.17 that the secretory protein subset provides a better
separation of cell lineages and cell types compared to nuclear
proteins. Phenotypic genes thus seem to be more highly
correlated on the mRNA–protein levels. Taken together, our
analyses show that multiple factors contribute to lowering the
correlation between mRNA and protein levels. Thus, proteome
analyses are likely to give more biologically relevant data on
dysregulated pathways in cancer than RNA expression analyses
alone.
Impact of copy number events. To study the impact of the extra
chromosomes in high hyperdiploid ALL, we ﬁrst compared the
mean RNA and protein expression according to copy number in
high hyperdiploid ALL. This clearly showed that the hyperdi-
ploidy is associated with dosage effects, i.e., a generally increasing
expression of genes and proteins with higher copy number (also
termed cis effects; Fig. 2a). Notably, however, not all genes and
proteins were affected in this way; approximately 16% (283/2,080)
of genes and 25% (523/2,080) of proteins instead showed negative
correlation with copy number. Thus, copy number gain does not
always lead to increased expression, in particular at the protein
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Fig. 1 Proteogenomic study of childhood B-cell precursor acute lymphoblastic leukemia (ALL). a Genomic landscape of 27 childhood ALL included in the
proteogenomic analysis. All cases were disomic for chromosomes 2, 19, and 20. b Numbers of proteins overlapping across the 3 TMT-sets. c Spearman’s
rank order correlation between mRNA and protein abundance. The correlation was positive for 77.6% mRNA-protein pairs in the whole cohort of cases
with a mean Spearman’s correlation coefﬁcient of 0.24. Approximately 23% mRNA-protein pairs showed signiﬁcant correlation (multiple-test adjusted P ≤
0.05). d When investigating different biological processes, mRNA and protein levels displayed the highest correlation for specialized pathways, such as
hematopoietic cell lineage and amino acid metabolism, and lowest for house-keeping functions, e.g., ribosomal and spliceosomal processes
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Fig. 2 Effects of copy number alterations on mRNA and protein abundance. a Dosage effects in 18 high hyperdiploid ALL at the RNA and protein levels. The
effects were lower on the protein level than on RNA level, showing additional layers of control for protein expression. b Cohen’s d effect size analysis of
gained chromosomes in high hyperdiploid vs. ETV6/RUNX1-positive leukemia. c cis and trans effects of copy number changes in 18 cases of hyperdiploid
childhood B-cell precursor acute lymphoblastic leukemia. Correlations of copy number aberrations (CNA) (x-axes) to RNA (top) and protein (bottom)
expression levels (y-axes) are shown. Note that a large fraction of the genome was not included in the analysis since there was no copy number variance,
either because all cases had two copies or because all cases had three copies. Signiﬁcant (multiple-test adjusted P < 0.05) positive (red) and negative
(blue) correlations between CNA and mRNAs/proteins are indicated. CNA cis effects appear as a red diagonal line, CNA trans effects as vertical stripes.
The fraction (%) of signiﬁcant CNA trans effects (positive in red and negative in blue) for each CNA gene is shown below. The bottom panel shows the
fraction (%) of leukemias harboring CNA (copy number gain in red and copy number loss in blue). Chromosomes that were gained in more than 16 cases
were not informative; their copy number is shown in gray
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level, presumably because of feedback loops controlling expres-
sion and protein turnover. Cohen’s d effect size analysis showed
that gain of chromosomes X, 14, and 21 was associated with
stronger dosage effects compared with the other commonly
gained chromosomes in both the RNA-seq and proteomics
datasets, with a linear relationship between normalized copy
number and effect size (Fig. 2b). Thus, our data clearly support
previous studies showing a general—albeit not ubiquitous—
upregulation of genes in high hyperdiploid ALL3,6. Furthermore,
we demonstrate that these dosage effects also are seen at the
protein level, with proteins encoded on the gained chromosomes
generally being more highly expressed.
To further investigate cis as well as trans (genes/proteins in
other genomic regions) effects of copy number changes, we used a
linear regression model to study the correlation between copy
number and expression (Fig. 2c and Supplementary Fig. 3)18. In
addition to the MS and RiboZero RNA-seq datasets, RNA
expression from a previously published RNA-seq study was
analyzed, comprising 83 cases (oligo(dT) RNA-seq; European
Genome-phenome Archive accession number EGAD00001002112;
Supplementary Data 1 and 6)19. In order to avoid outlier-driven
results, only 2080 genes displaying copy number variation
involving more than three cases were retained in the cis-effect
analysis. Again, cis dosage effects were seen, involving 25% (524/
2080) of genes and 12% (245/2080) of proteins at a signiﬁcance
level of P < 0.05 (Fig. 2c, Supplementary Fig. 3). Furthermore, trans
effects on the whole transcriptome and proteome were seen for all
informative regions. These were generally lower in the proteome
data, in particular for the long arm of chromosome 1 and
chromosomes 8, 17, and 21, which displayed very few trans effects
in the protein dataset. To further investigate the leukemogenic
impact of individual chromosomal gains, we mapped known
cancer driver genes to see whether they were associated with the
chromosomal pattern of high hyperdiploid ALL. That is, whether
oncogenes were more and tumor suppressor genes less commonly
located on the frequently gained chromosomes. However, no such
association was seen (Supplementary Fig. 3). Taken together, the
analysis of copy number and gene/protein expression conﬁrmed
that the extra chromosomes in high hyperdiploid ALL have a large
impact at RNA and protein levels in both cis and trans.
Protein expression differences between leukemic subtypes.
Next, we focused on expression differences between high
hyperdiploid and ETV6/RUNX1-positive ALL. To investigate
whether proteomics could be used to distinguish between high
hyperdiploid and ETV6/RUNX1-positive leukemia, hierarchical
cluster and principal component analyses were performed. The
two subtypes clustered separately in unsupervised analyses, both
by RNA and protein expression, in 27 cases (Fig. 3a). In
supervised analysis, 2423 genes and 1286 proteins were upre-
gulated and 2222 genes and 1127 proteins were downregulated
in high hyperdiploid cases compared with ETV6/RUNX1-posi-
tive cases (multiple-test adjusted P ≤ 0.05) (Supplementary
Data 4 and 5). Of these, 684 upregulated and 624 downregulated
genes and proteins overlapped (Supplementary Data 4 and 5).
Overall, there was a linear relationship between the log2 fold
changes of RNA-seq and proteomics data (Spearman’s correla-
tion coefﬁcient= 0.54, P < 2.2e−16) (Fig. 3b), with the corre-
lation being stronger for gene/protein pairs with high fold
changes.
Several of the top differentially expressed proteins have
previously been reported to play a role in leukemogenesis or to
be associated with ALL. These include, for example, CD44 and
FLT3 (Supplementary Data 4 and Supplementary Fig. 4), which
were highly expressed in high hyperdiploid cases. ETV6/RUNX1-
positive BCP-ALL has previously been reported to display a
CD44low-negative immunophenotype20, agreeing well with this
protein being differentially expressed by proteomics. In regards to
FLT3, the FLT3 gene harbors activating mutations in approxi-
mately 10–20% of high hyperdiploid ALL and has previously
been reported to be highly expressed in high hyperdiploid ALL
regardless of mutational status3,21. Here we show that this high
expression is maintained at the protein level, suggesting that
FLT3 may be involved in the leukemogenesis of high hyperdi-
ploid childhood ALL also in the absence of mutations. A
comparison with six sorted pro-B/pre-B samples—the normal
cells considered to be closest to ALL blasts—in the oligo(dT)
RNA-seq dataset conﬁrmed that CD44 and FLT3 were highly
expressed in the hyperdiploid leukemias (Supplementary Fig. 4).
Among the top-downregulated proteins in high hyperdiploid
cases were IGF2BP1, CLIC5, RAG1, and RAG2, which also
showed low RNA expression compared with the normal pro-B/
pre-B dataset (Supplementary Data 4 and Supplementary Fig. 4).
IGF2BP1 is recurrently involved in fusions with IGH@ in BCP
ALL and has previously been reported to be highly expressed in
ETV6/RUNX1-positive cases22,23. CLIC5 has been shown to be a
target of ETV6 and loss of ETV6 leads to its upregulation,
providing the cells with higher resistance to lysosome-mediated
apoptosis24. As regards RAG1 and RAG2, these are key
components of somatic V(D)J recombination and this process
has previously been shown to be involved in ETV6/RUNX1-
mediated leukemogenesis25, agreeing well with the high expres-
sion seen in our cohort. Taken together, the top differentially
expressed proteins obtained by MS agree well with previously
reported RNA expression results, supporting the validity of our
proteomics approach.
Gene set enrichment analysis (GSEA) was performed to
identify dysregulated pathways in BCP-ALL. Pathways that
were enriched in high hyperdiploid ALL in the protein analysis
could be divided into six different categories: (1) translation
and ribosomes, (2) innate immunity, (3) cell adhesion, (4)
cytokines and activated signaling, (5) protein folding and
proteolysis, and (6) the endosome (Fig. 3c and Supplementary
Data 7). Pathways that were enriched in ETV6/RUNX1-positive
cases comprised those related to: (1) chromatin organization,
modiﬁcation, and structure, (2) the G2/M checkpoint, and (3)
mitochondria (Fig. 3c and Supplementary Data 8). Support for
enrichment at the RNA level was seen for all these processes
expect pathways related to mitochondria, both in the RiboZero
and the oligo(dT) datasets (Supplementary Data 9–12). Taken
together, the GSEA results suggest an upregulation of transla-
tion and protein metabolism, including proteolysis and the
endosome, in high hyperdiploid ALL. This may be explained by
the additional transcription from the extra chromosomes,
which would be expected to result in a general increase in
translation. Furthermore, aneuploidy, in particular hyperdi-
ploidy, has been reported to be associated with a proteotoxic
stress response related to increased strain on the protein folding
pathways of the cell26, which could explain the enrichment for
protein folding and proteolysis seen here. The relative down-
regulation of pathways related to chromatin organization,
modiﬁcations and structure may be related to a higher
proliferative capacity of ETV6/RUNX1-positive cases, but could
also be associated with epigenetic events in high hyperdiploid
ALL, in particular in light of the changes in chromatin
organization that we found by high-resolution chromosome
conformation capture (Hi-C) in this subtype (see below).
That the G2/M checkpoint is enriched in ETV6/RUNX1-
positive cases, on the other hand, agrees well with the
previously reported importance of DNA recombination in such
cases25.
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Transcriptional dysregulation in high hyperdiploid ALL. We
further found that CTCF, as well as several members of the
cohesin complex, were signiﬁcantly lower expressed at both the
RNA and protein levels in our high hyperdiploid cases compared
with ETV6/RUNX1-positive cases as well as compared with
normal pro-B/pre-B cells (Fig. 4a, Supplementary Fig. 5). Ana-
lyses of the oligo(dT) RNA-seq dataset and two different publicly
available array-based gene expression datasets (GEO accession
numbers GSE13351 and GSE13425) conﬁrmed that the expres-
sion of both CTCF and cohesin seems to be particularly low in
high hyperdiploid ALL compared with other types of childhood
ALL (Supplementary Fig. 5). We did not observe any differences
in complex formation or correlation between the cohesin complex
members between the high hyperdiploid and the ETV6/RUNX1-
positive cases (Supplementary Fig. 5), indicating that there was a
general downregulation of gene/protein expression and not a
disturbance of the complex formation. CTCF has recently been
identiﬁed as a putative tumor suppressor gene in ALL and we
have previously reported a CTCF/PARD6A fusion that pre-
sumably results in disruption of the normal function of CTCF in
one case of high hyperdiploid ALL3,27. Besides being a tran-
scription factor, CTCF binds to chromatin at interphase and,
together with the cohesin complex, forms the basis for the for-
mation of topologically associating domains (TADs); chromatin
loops <1Mb in size containing DNA sequences that interact more
frequently with each other than with external sequences28. TADs
are generally conserved between different tissues and their dis-
ruption leads to changes in gene expression when the insulating
function of the TAD boundaries is lost28. Thus, CTCF and
cohesin are master regulators of transcription.
We hypothesized that this low expression of CTCF and cohesin
could have genome-wide effects on the transcriptional regulation
in high hyperdiploid ALL. To address this, we ﬁrst investigated
whether the differences in gene expression between high
hyperdiploid and ETV6/RUNX1-positive ALL were associated
with the number of CTCF binding sites in gene bodies and the
ﬂanking 5 kb, i.e., genes regulated by CTCF binding. We found
that differentially expressed genes in both the oligo(dT) and
RiboZero RNA-seq datasets were strongly enriched for more
CTCF binding sites compared with genes that showed similar
expression in the two ALL subtypes (chi-square test; P= 3.41e
−05 and P= 1.549e−05, respectively; Supplementary Fig. 6), in
line with the previous experimental data from a mouse model
with reduced CTCF expression29. Furthermore, genes with higher
numbers of CTCF binding sites showed larger fold changes in
both datasets (Supplementary Fig. 6). We also classiﬁed genes as
anchor genes or background genes based on the distance of their
transcription start sites to the closest CTCF/cohesin anchors,
forming the basis for chromatin loops, according to published
chromatin interaction analysis with paired-end tag sequencing
(ChIA-PET) data30. We found that a signiﬁcantly higher
proportion of the genes that were differentially expressed between
high hyperdiploid and ETV6/RUNX1-positive leukemias were
anchor genes in both the oligo(dT) and the RiboZero RNA-seq
datasets (hypergeometric test; P= 0.0139 and P= 0.00513,
respectively; Supplementary Fig. 7). Furthermore, differentially
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between changes on the transcript and translation levels of an individual gene product. The correlation was stronger for gene/protein pairs with high fold
changes. Signiﬁcant changes found in both RNA-seq and LC-MS/MS are shown in red, inverse changes found in RNA-seq and LC-MS/MS in yellow,
signiﬁcant changes found only in LC-MS/MS in green, and changes only found in RNA-seq in purple. c Gene set enrichment analysis of protein data
highlighted sets of pathways that were signiﬁcantly different between high hyperdiploid and ETV6/RUNX1-positive cases
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expressed anchor genes showed signiﬁcantly higher fold changes
(Mann–Whitney U-test; P= 6.6e−6 and P= 1.31e−4, respec-
tively; Supplementary Fig. 7), suggesting that a portion of
differentially expressed genes between hyperdiploid and
ETV6/RUNX1-positive cases were the result of changes in CTCF
binding.
To further investigate how the low levels of CTCF and cohesin
affected genome-wide transcription, we used publicly available
data to classify gene pairs according to whether they should be
divided by a TAD boundary or not, since the overall TAD
structure is generally conserved in human tissues31. We then
investigated whether their expression was correlated. First, we
analyzed RNA-seq data from a large cohort of childhood ALL
(n= 201) including all genetic subtypes19, from normal bone
marrow (n= 20)19, from acute myeloid leukemia (TCGA-LAML,
https://portal.gdc.cancer.gov/projects/TCGA-LAML; n= 151)32
and from papillary renal-cell carcinoma (TCGA-KIRP, https://
portal.gdc.cancer.gov/projects/TCGA-KIRP; n= 270)33. These
datasets all clearly displayed higher correlation between the
expression of gene pairs within the same TAD compared with
gene pairs separated by a TAD boundary (Supplementary Fig. 8),
showing that the TAD structure used in the analysis corre-
sponded well with actual transcriptional regulation and was in
line with previous studies34. We then performed the same
analysis in high hyperdiploid (n= 44) and ETV6/RUNX1-positive
(n= 39) cases separately. Whereas the ETV6/RUNX1-positive
leukemias showed a difference between intra- and inter-TAD
gene pairs, similar to the other datasets investigated, no
correlation with the expected TAD structure was observed in
the high hyperdiploid samples (Fig. 4b). Analysis of two publicly
available array-based gene expression datasets from childhood
ALL (GEO accession numbers GSE13351 and GSE13425)
conﬁrmed that high hyperdiploid ALL displayed aberrant
expression in relation to the expected TAD structure (Supple-
mentary Fig. 8). Restricting the analysis to only the commonly
trisomic or only the commonly disomic chromosomes did not
change the result (Supplementary Fig. 8), suggesting that the
phenomenon is not directly associated with the copy number of
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Fig. 4 Low CTCF/cohesin expression and transcriptional dysregulation in high hyperdiploid leukemia. a Boxplots of the expression of CTCF and members
of the cohesin complex in proteomics (top) and RiboZero RNA-sequencing datasets (bottom). Low expression of CTCF/cohesin complex members was
seen in the high hyperdiploid subgroup at both the RNA and protein levels. The center of the boxplot is the median and lower/upper hinges correspond to
the ﬁrst/third quartiles; whiskers are 1.5 times the interquartile range and data beyond this range are plotted as individual points. b Spearman’s correlation
coefﬁcient between gene pairs as a function of distance across the oligo(dT) RNA-sequencing dataset for ETV6/RUNX1-positive cases (left; n= 39) and
high hyperdiploid ALL (right; n= 44). The analysis showed that the expression of gene pairs in the same topologically associating domain (TAD; red)
displayed higher correlation than those in different domains (blue) or randomly selected regions (gray) in ETV6/RUNX1-positive cases, whereas no
difference was seen in high hyperdiploid ALL, suggesting that transcriptional dysregulation in hyperdiploid cases is related to TAD borders
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individual chromosomes. Taken together, the analyses suggest
that high hyperdiploid ALL exhibits an aberrant gene expression
pattern associated with changes in DNA looping.
TAD boundaries in high hyperdiploid ALL. To investigate
further the TAD organization in childhood ALL, we performed
in situ Hi-C analysis on four high hyperdiploid and two ETV6/
RUNX1-positive cases (Supplementary Data 13). Raw sequencing
data were processed using the HiCUP pipeline35, resulting in
230–320 million unique valid sequence tags per sample. An
average of 3450 TADs (range 2965–3960) was identiﬁed per case
by Domaincaller at 25 kb resolution with a mean size of ~740 kb
(range 645–845 kb) (Supplementary Data 13). The average
number of boundaries was 4230 (range 3853–4659) (Supple-
mentary Data 13). The majority of TAD boundaries were
expected to be bound by the insulator protein CTCF (86%) and
the cohesin subunit RAD21 (80%), in line with previous reports
(Supplementary Data 13)31. Comparing the TAD boundaries of
our samples with the high resolution Hi-C dataset from the
human lymphoblastoid cell line GM12878 31 showed that
approximately 70% of the TAD boundaries we found were also
present in GM12878, indicating that the overall TAD structure
was intact in the leukemia samples (Fig. 5, Supplementary
Data 13).
We then investigated whether the low expression of CTCF/
cohesin affects higher-order segregation of active and inactive
chromosome domains into A and B compartments. We
determined the compartment types of the genome at 500 kb
resolution in leukemia samples as well as GM12878 cell line
using Juicer eigenvector36. Overall, most (>90%) genomic
regions were in the same compartment in the leukemia samples
as in the GM12878 cell line and more than 98% of genomic
regions were in the same compartment in high hyperdiploid ALL
and ETV6/RUNX1-positive cases, in line with previous studies
showing that depletion of CTCF does not lead to compartment
switching37.
Comparing ETV6/RUNX1-positive and high hyperdiploid cases,
the number of TAD boundaries were reduced and the average
TAD structure length was increased by 21–120 kb in three of four
high hyperdiploid ALL. The exception (case HeH_42) had an
average TAD length of 645 kb (Supplementary Data 13). This
increase in TAD lengths in the three hyperdiploid cases resulted
from the partial fusion of multiple TADs into one, in line with the
decrease in the number of TAD boundaries. In order to analyze
changes in chromatin organization, we focused on recurrent
changes in boundaries detected in the different subgroups of
leukemia. One hundred thirty-one boundaries were weakened or
absent in at least two high hyperdiploid samples whereas only 14
boundaries were absent in both ETV6/RUNX1-positive cases
(Fig. 5 and Supplementary Data 14). Most of the corresponding
boundaries overlapped CTCF-cohesin binding sites (127/131,
97%), indicating that the loss of TAD boundaries was associated
with loss of a functional CTCF/cohesin complex in high
hyperdiploid samples (Supplementary Data 14). We then checked
the expression of mRNA and proteins in the RiboZero RNA-seq
and MS datasets. Of the 298 expressed mRNAs and 210 expressed
proteins encoded within 1Mb of the lost boundaries, signiﬁcant
(multiple-test adjusted P ≤ 0.05) expression differences between
high hyperdiploid and ETV6/RUNX1-positive ALL could be seen
for 134 (45%) and 65 (31%), respectively (Supplementary Data 15).
Of these differentially expressed genes/proteins, 98/134 (73%)
genes and 42/64 (66%) proteins were downregulated in high
hyperdiploid samples, which was more often than by chance (chi-
square test, P= 4.6e−9 for RNA-seq, and P= 0.0032 for
proteomics). This indicates that changes in chromatin
organization caused by CTCF/cohesin complex depletion tend to
downregulate gene expression in high hyperdiploid cases.
Although the global chromosomal interaction pattern appeared
largely unchanged between high hyperdiploid, ETV6/RUNX1-
positive cases and the cell line GM12878, closer inspection
showed differences in the strength of internal interactions within
TADs. To test whether the TAD interaction strength was affected,
we used directionality index and insulation score analyses to
calculate the ratio of interactions found within TADs versus those
spanning a boundary38,39. We found a genome-wide change in
directionality index as well as in insulation score between cases:
two high hyperdiploid cases (HeH_9 and HeH_10) showed a
clear loss of boundary strength based on directionality index
analysis and three (HeH_9, HeH_10, and HeH_48) showed
reduced insulation based on insulation score analysis compared
with the GM12878 cell line (Fig. 6). Thus, whereas the position of
TAD boundaries remained largely unchanged in high hyperdi-
ploid ALL samples, their quality was affected by changes in local
and distal interactions, with a fraction of TADs losing insulation
strength. This suggests that at least a subset of high hyperdiploid
ALL have signiﬁcant loss of insulation at TAD borders, agreeing
well with the observed transcriptional dysregulation in this
subgroup.
Poor metaphase chromosome morphology in hyperdiploid
ALL. To further explore the possibility of an aberrant chromatin
organization in high hyperdiploid ALL, we next focused on the
metaphase chromosomes. Metaphase chromosome morphology,
corresponding to the number of bands obtained with banding
techniques as well as the size and general appearance of the
chromosomes, varies between different cells and tissues. CTCF is
bound to chromatin throughout the cell cycle and it has been
suggested that it also affects the metaphase chromosome archi-
tecture40. We, therefore, hypothesized that high hyperdiploid
ALL may have aberrant chromosome morphology. In fact, a
common opinion among hematological cytogeneticists is that this
genetic subtype displays particularly poor chromosome mor-
phology, although this has not, to the best of our knowledge, been
properly investigated. To address this issue, we developed a scale
from 1 to 3 (1 corresponding to poor and 3 to good morphology;
Fig. 7) for scoring chromosome morphology (chromosome
morphology score; CMS) in a consistent manner and applied it to
37 cases of high hyperdiploid ALL and 33 cases of ETV6/RUNX1-
positive ALL. Although the CMS varied between cells within the
same case, there were clear differences in the mean values
between cases (Supplementary Data 16). Furthermore, the
investigation revealed a difference in mean CMS between the two
genetic subtypes, with high hyperdiploid ALL displaying sig-
niﬁcantly lower CMS, corresponding to poorer chromosome
morphology (Mann–Whitney one-sided test; P= 0.0075; mean
CMS 1.8 vs. 2.1; Fig. 7; Supplementary Data 16). Thus, metaphase
chromosomes of high hyperdiploid ALL show signs of an aber-
rant chromatin organization, in line with our RNA-seq and Hi-C
results.
Discussion
We here report a full-scale proteogenomic analysis of childhood
ALL, including the two largest subtypes of this disease that
together constitutes more than half of cases. The investigation
encompassed more than 8000 proteins and 12,000 RNAs in
genetically well-characterized cases. To the best of our knowledge,
only primary tumor samples from rhabdomyosarcoma, colon and
rectal, prostate, and breast cancer have previously been subjected
to proteogenomic analyses to this level9–11,41. Although many
previous studies of childhood ALL have utilized RNA expression,
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ﬁrst with microarrays and more recently with RNA-seq3,6,7, the
protein levels are expected to have a more direct impact on the
phenotype and our proteome analysis thus provides an improved
insight into leukemogenesis.
Previous studies of RNA expression in high hyperdiploid ALL
have shown clear dosage effects3,6,7, i.e. a general upregulation of
genes on the gained chromosomes, corresponding to cis effects.
However, no data on the effect on protein expression or in-depth
analyses of cis and trans effects in relation to the gained chro-
mosomes have been published to date. Here, we show that the
gained chromosomes in high hyperdiploid ALL are also asso-
ciated with cis effects at the protein level, but that those effects are
weaker than at the RNA level. In addition, we also identiﬁed a
general dysregulation of gene expression in relation to TAD
boundaries in high hyperdiploid ALL. This corresponds to a likely
disturbance in the insulation between regulatory elements and
gene promoters that should be separated by a TAD boundary.
Depleting CTCF experimentally has been associated with loss of
insulation at TAD borders in a dose-dependent manner, whereas
cohesin loss has been linked to lower insulation between TADs as
well as depletion of TADs37,42,43. Thus, it is feasible that the
relatively low expression of CTCF and cohesin that is seen in high
hyperdiploid ALL could affect TAD border insulation and/or
TAD structure. In line with this, our Hi-C analysis revealed that
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Fig. 5 Hi-C of high hyperdiploid and ETV6/RUNX1-positive cases. a Contact matrices from chromosome 3, selected because it is disomic in all cases and
displays no structural aberrations. The whole chromosome at 250 kb resolution is shown to the left and the 161–172Mb region at 25 kb resolution to the
right. At a resolution of 250 kb, the interaction proﬁle is similar, showing that the general chromatin architecture is intact. However, at a resolution of 25 kb,
it can clearly be seen that two of the high hyperdiploid cases (HeH_9 and HeH_10) have lost some topologically associating domains. b A/B compartment
proﬁle of chromosome 3 in cell line GM12878 and the six leukemia samples at 500 kb resolution. The proﬁles were similar between the cell line and the
leukemias
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three of four investigated high hyperdiploid samples displayed
weaker TAD boundaries than the remaining leukemias and
control cell lines, although the relatively small number of samples
investigated prevents deﬁnite conclusions. Additionally, a higher
number of TAD boundaries were recurrently lost in high
hyperdiploid cases compared with the ETV6/RUNX1-positive
cases and the cell lines. Furthermore, we found that high
hyperdiploid ALL display an aberrant chromosome metaphase
morphology, also suggesting an aberrant chromatin architecture.
The underlying cause of the low CTCF and cohesin expression in
high hyperdiploid ALL is currently unknown but mutations are
unlikely to be the general cause; although these do occur, the
frequency is relatively low3. CTCF is encoded on chromosome 16,
which is rarely gained2, whereas the core members of the cohesin
complex are all encoded on commonly gained chromosomes
(8q24 for RAD21, 10q25 for SMC3, Xp11 for SMC1A and Xq25
for STAG2); thus, the speciﬁc aneuploidy in high hyperdiploid
ALL may cause relatively low expression of CTCF but not of
cohesin.
Taken together, we show that the chromosomal gains in high
hyperdiploid ALL are associated with genome-wide effects on
Fig. 7 Metaphase chromosome morphology in hyperdiploid leukemia. High
hyperdiploid childhood acute lymphoblastic leukemia samples displayed
varying metaphase chromosome morphology, but the majority of cases had
poor morphology. a Example of metaphase with score 1—poor morphology
(case HeH_33). b Example of metaphase with score 2—fair morphology
(case HeH_48). c Example of metaphase with score 3—good morphology
(case HeH_48)
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Fig. 6 Weaker topologically associating domain (TAD) boundaries in high
hyperdiploid samples. a Median standardized directionality index proﬁles
around TAD boundaries identiﬁed in high hyperdiploid cases (red), ETV6/
RUNX1-positive cases (blue) and the GM12878 cell line (black). Two high
hyperdiploid cases (HeH_9 and HeH_10) showed markedly decreased
boundary strength, indicating permissive TAD boundaries. b Median
insulation score around the TAD boundaries identiﬁed in high hyperdiploid
cases (red), ETV6/RUNX1-positive cases (blue) and the GM12878 cell line
(black). Three high hyperdiploid cases (HeH_9, HeH_10, and HeH_48)
showed decreased insulation signal amplitude suggesting weaker insulation
between TADs compared to the remaining samples
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transcription. Furthermore, we show genome-wide transcrip-
tional dysregulation with putative leukemogenic effects in relation
to TAD borders in the hyperdiploid subtype suggestive of changes
in chromatin architecture; such changes could also be seen by Hi-
C in a subset of cases. Whether aberrant chromatin architecture is
a common phenomenon in aneuploid tumors remains an open
question.
Methods
Patients. The study comprised a total of 48 high hyperdiploid and 41
ETV6/RUNX1-positive pediatric BCP-ALL cases that had been treated at Skåne
University Hospital, Lund, Sweden, selected based on samples being available from
diagnosis (Supplementary Data 1). The cohort included 52 boys and 37 girls, with a
median age at diagnosis of 4 years (range 0–16) and a median white blood cell
count of 7.8 × 109/l (range 0.9–164). All cases had been tested for BCR/ABL1,
ETV6/RUNX1, PBX1/TCF3 and KMT2A (previously MLL) rearrangements by
reverse-transcriptase PCR, ﬂuorescence in situ hybridization, or Southern blot as
part of the clinical analyses and were found to be negative for these fusion genes,
with the exception of the ETV6/RUNX1 fusion in that subgroup. Informed consent
was obtained according to the Declaration of Helsinki and the study was approved
by the Ethics Committee of Lund University.
DNA and RNA extraction. Details for samples subjected to oligo(dT)-based RNA-
seq have been published elsewhere19. For samples subjected to mass spectrometry
analysis, DNA, total RNA and proteins were extracted from bone marrow or
peripheral blood samples obtained at diagnosis and stored in TRIzol (Thermo-
Fisher Scientiﬁc, Waltham, MA) at −80 °C for 4–17 years. After addition of
chloroform, RNA and DNA were precipitated according to the manufacturer’s
instructions. The remaining fractions containing proteins were stored at −80 °C.
Sample preparation for mass spectrometry. The stored TRIzol fractions were
thawed and loaded into Slide-A-lyzer cassettes (ThermoFisher Scientiﬁc, 3.5-kDa
cut-off, cat no 87722) and dialyzed according to the manufacturer’s instructions
against an aqueous solution containing 0.25% SDS and 25 mM Hepes pH 7.6
overnight at 4 °C with two changes of the dialysis buffer. The dialyzed samples were
digested by a modiﬁed FASP-protocol5. Protein concentrations were estimated by
gel staining and approximately 250 µg of each sample was mixed with 1 mM DTT,
8M urea, 25 mM HEPES, pH 7.6 and transferred to a 10-kDa cut-off centrifugation
ﬁltering unit (Pall, Nanosep®, Merck, Darmstadt, Germany), and centrifuged at
14,000 × g for 15 min. Proteins were alkylated by 50 mM iodoacetamide (IAA) in 8
M urea, 25 mM HEPES for 10 min. The proteins were then centrifuged at 14,000 ×
g for 15 min followed by two more additions and centrifugations with 8M urea, 25
mM HEPES. Proteins were digested at 37 °C with gentle shaking overnight by
addition of Lys-C (enzyme:protein= 1:50, Wako Pure Chemical Industries, Ltd.) in
500 mM Urea, 50 mM HEPES pH 7.6 followed by an additional overnight digestion
with trypsin (enzyme:protein= 1:50, ThermoFisher Scientiﬁc) in 50 mM HEPES,
pH 7.6. The ﬁlter units were centrifuged at 14,000 × g for 15 min followed by
another centrifugation with MilliQ water and the ﬂow-through was collected.
Peptides were cleaned up by a modiﬁed sp3-protocol44. Brieﬂy, carboxylate-
modiﬁed paramagnetic beads (ThermoFisher Scientiﬁc; CAT No. 09-981-121 and
ThermoFisher Scientiﬁc; CAT No. 09-981-123) were mixed 1:1 and washed with
MilliQ water. 10 µl of the bead-mixture was added to each peptide sample. Acet-
onitrile was added so that the ﬁnal concentration was >95% and beads were
incubated at room temperature for 8 minutes. Next, beads were placed on a
magnetic rack, the supernatant discarded and the beads washed twice with 180 µl of
acetonitrile. Beads were re-suspended in 100 µl of MilliQ water and sonicated to
release the peptides, supernatants were collected and stored at −20 °C. Peptide
concentration was determined by the Bio-Rad DCC assay and 30 µg of peptides
from each digested sample was labeled with TMT 10-plex reagent according to the
manufacturer’s protocol (ThermoFisher Scientiﬁc). A small portion of unlabeled
peptides were pooled from all samples to generate an internal standard that was
labeled with TMT-channel 131 and included in all sets. Labeled samples were
pooled, cleaned by strata-X-C-cartridges (Phenomenex, Torrance, CA) and dried
in a Speed-Vac.
Peptide level sample fractionation through HiRIEF. The TMT labeled peptides,
300 µg, were separated by immobilized pH gradient - isoelectric focusing (IPG-IEF)
on pH 3–10 strips using the HiRIEF method45. Peptides were extracted from the
strips by a prototype liquid handling robot, supplied by GE Healthcare Bio-
Sciences AB. A plastic device with 72 wells was put onto each strip and 50 µl of
MilliQ water was added to each well. After 30 minutes incubation, the liquid was
transferred to a 96 well plate and the extraction was repeated two more times with
35% acetonitrile (ACN) and 35% ACN, 0.1% formic acid in MilliQ water,
respectively. The extracted peptides were dried in Speed-Vac and dissolved in 3%
ACN, 0.1 % formic acid.
Mass spectrometry based quantitative proteomics. Extracted peptide fractions
were separated using an Ultimate 3000 RSLCnano system coupled to a Q Exactive
(ThermoFisher Scientiﬁc). Samples were trapped on an Acclaim PepMap nanotrap
column (C18, 3 µm, 100 Å, 75 µm × 20 mm, ThermoFisher Scientiﬁc), and sepa-
rated on an Acclaim PepMap RSLC column (C18, 2 µm, 100 Å, 75 µm x 50 cm,
ThermoFisher Scientiﬁc). Peptides were separated using a gradient of mobile phase
A (5% DMSO, 0.1% FA) and B (90% ACN, 5% DMSO, 0.1% FA), ranging from 6
to 37 % B in 60 min (depending on IPG-IEF fraction complexity) with a ﬂow of
0.25 µl/min. The Q Exactive was operated in a data-dependent manner, selecting
top 10 precursors for fragmentation by HCD. The survey scan was performed at
70,000 resolution from 400–1600 m/z, with a max injection time of 100 ms and
target of 1 × 106 ions. For generation of HCD fragmentation spectra, a max ion
injection time of 140 ms and AGC of 1 × 105 were used before fragmentation at
30% normalized collision energy, 35,000 resolution. Precursors were isolated with a
width of 2 m/z and put on the exclusion list for 70 s. Single and unassigned charge
states were rejected from precursor selection.
Peptide and protein identiﬁcation. Orbitrap raw MS/MS ﬁles were converted to
mzML format using msConvert from the ProteoWizard tool suite45. Spectra were
then searched using MSGF+ (v10072)46 and Percolator (v2.08)47, where search
results from eight subsequent fraction were grouped for Percolator target/decoy
analysis. All searches were done against the human protein subset of Ensembl 75 in
the Galaxy platform. MSGF+ settings included precursor mass tolerance of 10
ppm, fully-tryptic peptides, maximum peptide length of 50 amino acids and a
maximum charge of 6. Fixed modiﬁcations were TMT-10plex on lysines and
peptide N-termini, and carbamidomethylation on cysteine residues, a variable
modiﬁcation was used for oxidation on methionine residues. Quantiﬁcation of
TMT-10plex reporter ions was done using OpenMS project’s IsobaricAnalyzer
(v2.0)48. Peptide-spectrum matches (PSMs) found at 1% false discovery rate (FDR)
were used to infer gene identities. Protein quantiﬁcation by TMT 10-plex reporter
ions was calculated using TMT PSM ratios to the entire sample set (all 10 TMT-
channels) and normalized to the sample median. The median PSM TMT reporter
ratio from peptides unique to a gene symbol was used for quantiﬁcation. Protein
false discovery rates were calculated using the picked-FDR method using gene
symbols as protein groups and limited to 1% FDR49.
DNA sequencing analyses. WGS results for cases HeH_2, HeH_3, HeH_12,
HeH_13, HeH_17, HeH_22, HeH_24, HeH_25, HeH_27, HeH_32, HeH_35,
HeH_38, and HeH_43 and WES results for cases HeH_1, HeH_4, HeH_5, HeH_7,
HeH_8, HeH_16, HeH_19, HeH_26, HeH_34, HeH_37, and HeH_41 have been
previously published3. Brieﬂy, for WGS, matched diagnostic and remission bone
marrow or peripheral blood samples were sequenced to ~100x coverage on the
Complete Genomics platform. Somatic events were identiﬁed using the Complete
Genomics Cancer Sequencing v2.0 pipeline with CGA tools. For WES, libraries
were constructed using the SureSelectXT2 Human All Exon V4 kit (Agilent
Technologies, Santa Clara, CA) from matched diagnostic and remission bone
marrow or peripheral blood samples and paired-end sequencing were done to
~120x coverage on an Illumina HiSeq2000. Somatic mutations were detected with
MuTect50. WES for cases HeH_6, HeH_9-HeH_11, HeH_14, HeH_15, HeH_18,
and ETV6/RUNX1_1-ETV6/RUNX1_9 were done by Nextera Rapid Capture
Expanded Exome Kit (Illumina, San Diego, CA, USA), with ~110x coverage on an
Illumina NextSeq 500. Paired remission samples were available from cases HeH_6,
HeH_10, HeH15, ETV6/RUNX1_1-ETV6/RUNX1_5, and ETV6/RUNX7_1-
ETV6/RUNX1_9. Pair-end sequence reads were aligned to the human_g1k_v37 by
Burrows-Wheeler Aligner (BWA)51. Duplicate reads were marked with Picard and
Indel realignment was performed with GATK52. Somatic mutations were identiﬁed
using MuTect50 and MuSE53 whereas somatic indels were identiﬁed by manta54
and strelka55 with default settings. Mutations that passed the internal ﬁlters of the
variation caller were further ﬁltered by a minimum depth of 10 reads. For tumor
samples without matched normal (HeH_9, HeH_11, HeH_14, HeH_18 and ETV6/
RUNX1_6), variations were identiﬁed by GATK UniﬁedGenotyper and annotation
parameters QD (variant conﬁdence/quality by depth) <2.0, MQ (RMS mapping
quality) <40.0, FS (Fisher strand) 60.0, HaploTypeScore >13.0, MQRankSum <
−12.5 and ReadPosRankSum <−8.0 were used to ﬁlter low quality variations.
High-quality variants were further ﬁltered by 1000 Genomes (20110521 release),
ESP6500, ExAC, CG46 (popfreq_max_20150413) and 170 million variants
(kaviar_20150923) provided by ANNOVAR56 to remove potential SNP sites.
Functional annotation was performed by ANNOVAR.
SNP array analyses. SNP array analysis was done on DNA extracted from
diagnostic bone marrow or peripheral blood samples on the Human1M-Duo,
Human-Omni1-Quad, Human-Omni5-4v (Illumina, San Diego, CA), or CytoScan
HD platforms (Applied Biosystems, Thermo Fisher); data have been published
previously57.
RNA-sequencing. Details on the oligo(dT) RNA-seq dataset have been previously
published19. Brieﬂy, cDNA sequencing libraries were constructed from poly-A-
selected RNA using the Truseq RNA library preparation kit v2 (Illumina, San
Diego, CA) and sequenced on an Illumina HiScan SQ or an Illumina NextSeq 500.
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For the RiboZero RNA-seq, RNA from cases HeH_1-HeH_18 and ETV6/
RUNX1_1-ETV6/RUNX1_9 were constructed using the Human Ribo-Zero rRNA
Removal Kit (Illumina, San Diego, CA) and sequenced on an Illumina NextSeq
500.
Expression analyses. RNA sequencing data were processed using the TCGA
mRNA-seq pipeline (https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/
Expression_mRNA_Pipeline/#mrna-analysis-pipeline). Brieﬂy, sequencing reads
were aligned to the human GRCh38 genome assembly using STAR58 and read
counts for each gene were obtained by HTSeq-count59.
Genes with count-per-million (CPM) value greater than 1 were deﬁned as
expressed genes and only genes expressed in more than 80% of samples in at least
one sample group were used for further analyses. For differential expression analysis,
batch effects were adjusted by using RUVg function in RUVSeq60 and differentially
expressed genes were identiﬁed by using edgeR61. Benjamini–Hochberg adjusted
(BH-adjusted) P ≤ 0.05 were used as cutoff. In the oligo(dT) dataset, six samples
representing sorted pro-B (CD34+CD38+CD19+CD10+) or pre-B (CD34−
CD38+CD19+CD20−CD10+) cells were included and used to compare leukemic
samples to the closest normal cell.
For the proteomics dataset, absolute intensity values of the PSMs were
converted to ratios based on the pool reference and log2 transformed. Spectra
mapping to unique gene symbols were retained and aggregated to proteins using
the median value of the PSM ratios. Proteins identiﬁed in all sets were used for
subsequent analysis. To remove the batch effects of proteomics data, iterative
RUV4 algorithm was used62. In brief, we initialized the search with the median
normalized dataset to detect the proteins with BH-adjusted P greater than 0.9 as
the ﬁrst controls by using limma63. In each of the 10 iterations, we applied the
RUV4 algorithm on the un-normalized data to obtain the residuals and calculate ab
initio the control proteins as those with differential abundance of BH-adjusted P
greater than 0.9. These proteins were used as control proteins in the next iteration.
Control proteins identiﬁed in the last iteration constituted the empirical controls
which were uncorrelated to the tumor category. Protein differential expression
analysis was performed by limma and BH-adjusted P ≤ 0.05 was applied as cutoff
for identifying differentially expressed proteins.
Two gene expression datasets obtained from NCBI Gene Expression Omnibus
(accession numbers GSE13351 and GSE13425) were analyzed. The expression data
were analyzed using Transcriptome Analysis Console (Affymetrix, Santa Clara, CA,
USA) with default settings.
Correlation between mRNA and protein variation. To compare mRNA and
protein variations across samples, we focused on 8222 genes/proteins that were
detected in both the Ribozero RNA-seq dataset and the proteomics dataset. We
ﬁrst calculated the Spearman’s correlation coefﬁcient between RNA-seq FPKM
values and RUV4-normalized values from the proteomics dataset across samples
(n= 27) and P-values corresponding to the coefﬁcients were computed and
adjusted by Benjamini–Hochberg procedure. Signiﬁcant calls were made based on
BH-adjusted P ≤ 0.05. Functional enrichment analysis was performed by GSEA-
Pre-ranked algorithm64 and Spearman’s correlation coefﬁcient was used as the
ranking variable. Pairwise correlation analysis of protein pairs, which are present
within the same complex of known protein complexes acquired from the CORUM
database65, were performed by using Spearman correlation’s coefﬁcient and the
same analysis was performed on the RiboZero RNA-seq dataset. For the mRNA-
protein stability analysis mRNA and protein half-lives from mouse ﬁbroblast cell
lines were extracted from Schwanhäusser et al.13 and analyzed as per the original
manuscript and Zhang et al.9, i.e., stable (unstable) mRNAs and proteins were
categorized according to their rank in the top (bottom) one third of half-lives,
respectively. For micro-RNA targeting analysis miRNA-mRNA interactome data
was downloaded from Helwak et al.14. For the analysis of the impact of ubiquiti-
nation and proteasomal degradation time-series ubiquitination data from HCT116
and 293T human cell lines upon bortezomib treatment was used15. We chose the 8-
hour point as a proxy for steady-state and divided signiﬁcantly/non-signiﬁcantly
ubiquitinated proteins according to an absolute log2 fold change greater/smaller
than 1. We also investigated the impact of protein degradation proﬁles, namely
exponential (ED) and non-exponential (NED) decay, using mouse ﬁbroblast cell
data from a click-chemistry assisted pulsed SILAC study16. Information on protein
subcellular localization was downloaded from a MS-based study on global sub-
cellular localization17 and used to subset our dataset. For the analysis of the impact
of differential expression/abundance on mRNA-protein correlations transcripts/
proteins were divided to signiﬁcant/non-signiﬁcant based on BH adjusted P-value
<0.05 and log2 fold changes higher (lower) than the 90% (10%) percentile. To
avoid correlations being driven by tumor subtype differences (Simpson’s paradox),
partial correlations were estimated after regressing the data on tumor subtype and
calculating Spearman correlations on the residuals. For the above analyses, we used
overlapped gene symbols between datasets. Two-group and multi-group compar-
isons were assessed with two-sided Wilcoxon rank sum test and Kruskal–Wallis
test, respectively.
Analysis of cis- and trans-effects. Matched copy number aberrations (CNA)
based on SNP-array analysis, WES and/or WGS, proteomics and RNA-seq
measurements of 18 high hyperdiploid samples were used to study the impact of
CNAs on mRNA and protein expression. In order to avoid outlier-driven results,
only genes displaying CNAs involving more than 3 cases in each comparison group
were retained (CNA genes, n= 2080). To analyze genome-wide cis effects of high
hyperdiploid ALL samples, Spearman’s correlation coefﬁcient between genes/pro-
teins abundance and copy number of 2080 informative CNA genes was calculated,
respectively. To analyze genome-wide trans effects, the correlation between CNA
genes and all 8222 mRNA and proteins detected in both RNA-seq and proteomics
of 18 high hyperdiploid samples were determined using the MatrixeQTL R
package18. Subsequently, P-values corresponding to the coefﬁcient were calculated
and signiﬁcant CNA-mRNA and CNA-protein correlations were identiﬁed using
BH-adjusted P-value 0.05 as cutoff.
To assess the impact of copy number aberrations on the hyperdiploid vs.
ETV6/RUNX1-positive ALL differential expression, a normalized copy number per
chromosome across the samples was calculated according to the formula:
Normalized copy number per chromosome
¼ Averagesamples
P# chromosomal segments
i¼1 copy number ðiÞ  length ðiÞ in bp
total length of chromosome
Normal ploidy ðfor somatic chromosomes2; for sex chromosomes1;2;NAÞ
0
B
@
1
C
A
ð1Þ
Cohen’s d effect size was calculated per chromosome at the mRNA and protein
level and linearly regressed on the normalized copy number. We denoted
signiﬁcantly affected chromosomes as those with effect size >0.3.
To estimate the differential expression of known cancer driver genes66 on the
mRNA and protein level based on edgeR and limma, respectively, fold changes
were overlaid on the ALL copy number landscape and gene symbols with BH-
adjusted P-values ≤0.05 and fold change greater (lower) than the 90th (10th)
percentile were displayed.
Gene set enrichment analysis. Gene set enrichment analysis64 was done using the
GSEA-pre-ranked algorithm with lists of all expressed genes (n= 12,313 for
Ribozero and n= 13,951 for oligo(dT), respectively) and all expressed proteins
(n= 8480), by using predictive log fold changes between high hyperdiploid ALL
and ETV6/RUNX1-positive cases generated by edgeR (RiboZero and oligo(dT)
RNA-seq) and log‐fold changes values generated by limma (LC-MS/MS) as the
ranking variable, respectively. We performed the analysis using the GSEA stan-
dalone software with default settings. Family-wise error rate (FWER) P < 0.05 was
considered signiﬁcant.
CTCF binding site and ChIA-PET data analysis. CTCF binding sites analysis was
done according to Aitken et al.29. We downloaded the positions of CTCF binding
sites from the ENCODE database (http://hgdownload.cse.ucsc.edu/goldenpath/
hg19/encodeDCC/wgEncodeAwgTfbsUniform/
wgEncodeAwgTfbsBroadGm12878CtcfUniPk.narrowPeak.gz) and the number of
CTCF binding sites in each gene (plus 5 kb on either side) were obtained by using
BEDTools (https://bedtools.readthedocs.io/en/latest/) command intersect. The
proportion difference between the differentially expressed genes group and the
remaining genes group was tested with the chi-square test and the difference
between fold changes according to number of CTCF binding sites was tested by
Mann–Whitney U-test. ChIA-PET data for CTCF and RAD21 were downloaded
from the NCBI GEO database under accession numbers GSM1872886 and
GSM1436265, respectively. To get high-conﬁdence chromatin interactions, ChIA-
PET interactions with low PET-count (less than ten reads coverage) were removed.
BEDTools was used to ﬁnd the overlapping interactions between CTCF and
RAD21 ChIA-PET datasets and only interactions detected in both datasets were
used. BEDTools command closest was used to determine the distance between the
transcription start sites of expressed genes and CTCF/cohesin anchors. Genes
located within 5 kb of a CTCF/cohesin anchor were deﬁned as anchor genes.
Statistical differences in the proportion of differentially expressed genes between
the anchor genes group and the background group were tested by hypergeometric
test and the differences between fold change values were tested with the
Mann–Whitney U-test.
Gene pair correlation analysis. Gene pair correlation analysis was done according
to Flavahan et al.34. Brieﬂy, TADs of the IMR90 and GM12878 cell lines were
downloaded from published Hi-C data31 (Gene Expression Omnibus accession
number GSE63525) and genes were assigned to the inner-most domain in which
the transcription start site of the canonical transcript fell within. Genes were
assigned to the same domain if they were assigned to the same domain in both
GM12878 and IMR90 datasets. Ten thousand randomly generated domains were
obtained by using BEDTools command random with 1Mb as interval size.
Spearman’s correlation coefﬁcient for all relevant gene pairs within the same TAD,
different TADs and randomly generated domains were calculated and the corre-
lation plot was smoothed by locally weighted scatterplot smoothing with weighted
linear least squares (LOESS).
Hi-C library preparation and sequencing. Hi-C was done on cases HeH_9, HeH-
10, HeH_42, HeH_48, ETV6/RUNX1_6, and ETV6/RUNX1_41, selected on the
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09469-3
12 NATURE COMMUNICATIONS |         (2019) 10:1519 | https://doi.org/10.1038/s41467-019-09469-3 | www.nature.com/naturecommunications
basis of sample availability. Cell pellets approximately 5 mm in size containing
mononuclear bone marrow or peripheral blood cells obtained at leukemia diag-
nosis were resuspended in 10 ml room temperature 1× PBS. The cells were ﬁxed by
the addition of 37% formaldehyde to a ﬁnal concentration of 2% and gentle mixing
on a rocker for 10 min at room temperature. The reaction was quenched by the
addition of 1.5 ml cold glycine (0.125M). Following incubation for 5 min at room
temperature and 15 min on ice, the cells were pelleted by centrifugation at 400×g
for 10 min at 4 °C. The pellet was resuspended in 1 ml cold 1× PBS by pipetting and
made up to a ﬁnal volume of 10 ml with cold 1× PBS. Finally, the cells were pelleted
by centrifugation at 400×g for 10 min at 4 °C, and the pellet snap-frozen and stored
at −80 °C until further analysis. In nucleus Hi-C on the crosslinked mononuclear
cells was performed as outlined in Nagano et al.67. Each sample was split into two
and processed separately to provide a technical replicate. One lane of 150 base pair
paired-end sequencing was performed on the Illumina HiSeq 4000 instrument per
replicate (12 lanes in all).
Hi-C data analysis. The sequences from the Hi-C libraries were mapped to
reference human_g1k_v37 using HICUP with default settings35. Redundant reads
and short-range Hi-C artifacts were removed from all downstream analyses. Fil-
tered read pairs were then aggregated into 25, 50 , and 100 kb genomic bins to
generate Hi-C contact matrices. Low-coverage bins were ﬁltered by using max-
imum allowed median absolute deviation (MAD-max) and low-coverage bins with
MAD-max values higher than 2 were removed. Reads mapped to the same bin or
adjacent bins were also removed. For the GM12878 cell line datasets, we down-
loaded.hic data from the NCBI GEO database (accession number GSE63525,
GM12878_insitu_primary+replicate_combined_30.hic.gz) and converted.hic for-
mat into 25, 50, and 100 kb contact matrices by using the dump option of Jui-
certools36. The same ﬁltering strategy was applied to the GM12878 cell line dataset.
The ﬁltered contact matrices were then normalized using the chromosome-
adjusted iterative correction procedure (caICB) to eliminate copy number bias68.
TAD and boundaries calling. The normalized 25 kb contact matrices of six leu-
kemia cases and GM12878 cell line were used to predict TAD structures by
DomainCaller39, as this showed the best agreement with manual annotation in a
previous study69. To ﬁnd the optimal threshold for TAD calling, the window size
parameter of DomainCaller was varied from 250 kb to 2Mb and ﬁnally 500 kb
window size was used, which showed about 80% of detected boundaries co-aligned
with the previously detected boundaries of the GM12878 cell line31 (accession
number GSE63525, GM12878_primary+replicate_Arrowhead_domainlist.txt.gz)
with ±100 kb precision. Standardized genome-wide directionality index value (z-
score value) was used for TAD analysis. InsulationScore package was also used to
identify TAD boundaries38. For insulation boundaries analysis, insulation square
was set to 250 kb and insulation delta span was set to 125 kb. Insulation score was
calculated for each chromosome and then normalized by the genome-wide median.
TAD analysis. When comparing TAD boundaries between high hyperdiploid ALL
and ETV6/RUNX1-positive cases, boundaries detected in different samples within
±100 kb were called overlapped boundaries while the recurrent boundaries found
only in one subgroup of leukemia samples were deﬁned as subgroup-speciﬁc
boundaries. To investigate loss of TAD boundaries in high hyperdiploid ALL, the
multiinter command in BEDTools software was used to identify the overlapped
boundaries and subgroup-speciﬁc boundaries. To further correlate the presence of
boundaries in the different subgroups of leukemia, the subgroup-speciﬁc bound-
aries were manually traced. Brieﬂy, balanced-corrected Hi-C matrices were plotted
using Juicebox36 and subgroup-speciﬁc boundaries were stratiﬁed into three
categories, (i) boundaries showing sharp visual contrast between within and across
TAD interaction frequencies were classiﬁed as strong boundaries, (ii) boundaries
showing little visual contrast were classiﬁed as weak boundaries and (iii) bound-
aries that totally disappeared in one of subgroup of leukemia cases were classiﬁed as
lost boundaries. To detect CTCF and RAD21 binding sites occupancy over the
subgroup-speciﬁc boundaries, peak ﬁles were downloaded from the UCSC database
(http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/
wgEncodeAwgTfbsUniform/) and the intersectBed command in BEDTools soft-
ware was used to identify all CTCF/RAD21 peaks located within a ±50 kb window
around the boundary.
Chromosome morphology analysis. Bone marrow or peripheral blood prepara-
tions and G-banding was performed according to standard methods from cells
obtained at diagnosis and stored in ﬁxative (methanol:acetic acid; 3:1) at −20 °C.
The slides were analyzed using an Eclipse 80i microscope (Nikon, Tokyo, Japan)
equipped with a progressive scan camera (JAI, Copenhagen, Denmark) and a ×100
oil immersion Plan Apo VC lens (Nikon). Metaphases were captured, edited and
karyotyped with the CytoVision software (Leica Biosystems, Wetzlar, Germany).
Each metaphase was scored from 1–3 according to chromosome morphology, as
judged by the level of chromosome condensation, the band resolution, overall
chromosome shape and clearness, and how easily the chromosome pairs could be
identiﬁed.
The criteria used for scoring were: 1—poor chromosome morphology, where no
substantial banding pattern could be observed, chromosomes were very condensed,
chromosomes presented a fuzzy appearance, i.e., chromosome shape was poor, and
homolog pairs were difﬁcult to identify; 2—fair morphology, where band level was
at 200–300, chromosomes were less constricted and presented a sharp appearance,
which made it easier to karyotype; and 3—good morphology, where the band levels
was at least 350–400, chromosomes were elongated and presented an ideal
appearance for cytogenetic analysis (Fig. 7). The person doing the chromosome
morphology investigation was blinded to the results from Hi-C analysis.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange70
Consortium (http://proteomecentral.proteomexchange.org) with the dataset identiﬁer
PXD010175. RNA-seq data have been deposited to the European Genome-phenome
Archive (EGA) under the accession code EGAS00001003079. The remaining data will be
available for academic research on somatic variants only by contacting the authors.
Publicly available data used in this study can be found as deposited in the following
datasets: Oligo(dT) RNA-seq data for ALL patients, accession number
EGAD00001002112. Expression data from ALL patients, accession numbers GSE13351
and GSE13425. RNA-seq dataset for AML, accession number TCGA-LAML. RNA-seq
dataset for papillary renal cell carcinoma, accession number TCGA-KIRP. Hi-C datasets
for GM12878 cell line and IMR90 cell line, accession number GSE63525. GM12878
CTCF ChIA-PET dataset, accession number GSM1872886. GM12878 RAD21 ChIA-PET
dataset, accession number GSM1436265.
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